First Line Therapy for Patients With Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2013-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the toxicity and anti-tumor activity of
nab-paclitaxel 100mg/m^2 administered weekly in a 4-week cycle as first line therapy to
patients with metastatic breast cancer who received taxanes as part of their adjuvant therapy
and patients who did not receive taxanes as part of their adjuvant therapy.